FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency
Pharmaceutical Technology
JULY 1, 2025
The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock. Sign up for our daily news round-up!
Let's personalize your content